Chester County News and Community Website
WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) appointed pediatric dermatologist James R. Treat as chief medical officer effective Dec. 21, putting a longtime clinical collaborator in charge of medical …
Palvella Names James Treat CMO as QTORIN Advances Toward Market Read More WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) Chief Executive Officer Wes Kaupinen will appear at two healthcare investor conferences in September, giving investors two near-term opportunities to hear from …
Palvella CEO to Pitch Rare-Disease Pipeline at Investor Meets Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) recently completed its U.S. application for approval of QTORIN™ rapamycin to treat microcystic lymphatic malformations, putting the Wayne-based biotechnology company on a …
ICYMI: Palvella Seeks FDA Approval for Rare-Disease Skin Therapy Read More WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) has completed its application for U.S. approval of QTORIN 3.9% rapamycin anhydrous gel to treat microcystic lymphatic malformations, moving the Wayne-based biotechnology …
Palvella Files FDA Bid for QTORIN Rapamycin in Rare Disease Read More WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) Chief Executive Officer Wes Kaupinen will address investors Wednesday at the Canaccord Genuity 46th Annual Growth Conference as the clinical-stage biotechnology company …
Palvella CEO to Address Investors at Canaccord Conference Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) began its rolling U.S. application for QTORIN rapamycin during the second quarter as higher clinical, manufacturing and regulatory spending more than doubled …
Palvella Advances FDA Filing as Drug Spending Lifts Loss Read More WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) Chief Scientific Officer Jeffrey Martini will address evidence gaps and regulatory barriers affecting drug repurposing at an Aug. 5 FDA public workshop …
Palvella Executive to Address FDA Drug Repurposing Barriers Read More WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) has appointed biotechnology executive Matt Pauls to its board of directors as the company prepares for a potential U.S. launch of its lead …
Palvella Adds Rare-Disease Executive to Board Ahead of Launch Read More WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) has submitted the first portion of its application seeking U.S. approval of QTORIN rapamycin, a treatment for microcystic lymphatic malformations, moving the company …
Palvella Begins FDA Filing for Rare Disease Drug Candidate Read More WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) has received U.S. Food and Drug Administration authorization for rolling review of its New Drug Application for QTORIN rapamycin, a step that could …
Palvella Secures FDA Rolling Review for Rare Disease Drug Read More